Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Iadademstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oryzon Bolsters Iadademstat Patent Portfolio With European Grant
    Oryzon Bolsters Iadademstat Patent Portfolio With European Grant

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159429/0/en/ORYZON-Strengthens-Patent-Portfolio-for-iadademstat-with-European-Grant-Decision-Covering-Combinations-with-PD1-PD-L1-Inhibitors.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150714/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Iadademstat-and-Vafidemstat-with-New-Decisions-to-Grant.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    ORYZON Doses First Patient in NCI Phase I/II Trial for Lung Cancer
    ORYZON Doses First Patient in NCI Phase I/II Trial for Lung Cancer

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061672/0/en/ORYZON-Announces-First-Patient-Dosed-in-NCI-Sponsored-Phase-I-II-Clinical-Trial-of-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Oryzon Presents Iadademstat Plus Gilteritinib Data At EHA 2024
    Oryzon Presents Iadademstat Plus Gilteritinib Data At EHA 2024

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898942/0/en/ORYZON-Presents-Preliminary-Data-From-Ongoing-Phase-Ib-FRIDA-Trial-with-Iadademstat-Plus-Gilteritinib-in-Relapsed-Refractory-FLT3-mut-AML-Patients-at-EHA-2024.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    ORYZON's Iadademstat ALICE Phase 2a Results Published In Lancet Hematology
    ORYZON's Iadademstat ALICE Phase 2a Results Published In Lancet Hematology

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892179/0/en/ORYZON-Announces-Journal-Publication-of-Final-Phase-IIa-ALICE-Results-with-Iadademstat-in-The-Lancet-Hematology.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    ORYZON Announces FDA Clearance of Iadademstat for SCLC
    ORYZON Announces FDA Clearance of Iadademstat for SCLC

    08 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/08/2859130/0/en/ORYZON-Announces-U-S-FDA-Clearance-of-CTEP-CRADA-Phase-I-II-Clinical-Trial-Sponsored-by-NCI-for-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-.html

    GLOBENEWSWIRE
    08 Apr 2024
    Share Share